Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay: A four-centre comparative trial

Journal of Immunological Methods

Volumn 244, Issue 1-2, 2000, Pages 81-89

  Scheibenbogen, Carmen ^a,f   Romero, Pedro ^b   Rivoltini, Licia ^c   Herr, Wolfgang ^d   Schmittel, Alexander ^a   Cerottini, Jean Charles ^b   Woelfel, Thomas ^d   Eggermont, Alexander M M ^e   Keilholz, Ulrich ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chromium release assay; ELISPOT assay; Limiting dilution assay

Indexed keywords

CHROMIUM; GAMMA INTERFERON; TUMOR ANTIGEN;

ARTICLE; ASSAY; BLOOD; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LABORATORY; MONONUCLEAR CELL; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHROMIUM RADIOISOTOPES; COMPARATIVE STUDY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HIV-1 REVERSE TRANSCRIPTASE; HLA-A2 ANTIGEN; HUMAN; IMMUNODOMINANT EPITOPES; INDICATOR DILUTION TECHNIQUES; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 0034693390     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00257-X     Document Type: Article

References (22)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. The minimum peptide epitope from the influenza virus matrix protein
3. Quantitative assay of the lytic action of immune lymphoid cells on 51Cr-labelled allogenic target cells in vitro; inhibition by isoantibodies and by drugs
4. Phenotypical and functional separation of memory and effector human CD8+ T cells
5. Detection and quantification of blood-derived CD8+ T lymphocytes secreting TNFα in response to HLA-A2.1-binding melanoma and viral peptide antigens
6. Induction of tyrosinase-specific CD8+ T cell response in a HLA-A2+ melanoma patient treated with IL-2-based chemoimmunotherapy
7. Rapid effector function in CD8+ memory T cells
8. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
9. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells
10. The expanding universe of T-cell subsets: Th1, Th2 and more
11. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
12. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests
13. Idiotype immunization combined with GM-CSF in myeloma patients induced type I, major histocompatibility complex-restricted, CD8+ and CD4+specific T-cell responses
14. Immunization of patients with melanoma peptides vaccines: immunologic assessment using the ELISPOT assay
15. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
16. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
17. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
18. Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELISPOT assay
19. Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma
20. Evaluation of the IFNγ ELISPOT-assay for quantification of peptide-specific T lymphocytes from peripheral blood
21. Quantitation of tumor-specific T cells with the ELISPOT assay
22. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis